Trial Profile

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab: An Umbrella Bayesian Optimal Phase II Study.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golcadomide (Primary) ; Nivolumab (Primary) ; Rituximab (Primary)
Indications Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms TOP-FLOR

Most Recent Events

04 Jun 2024 Study design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition
30 Aug 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com